Search results.

Compare 4 exact-size AOD-9604 research listings, including 3 confirmed in-stock rows, the $44.00 current low, and 3 in-stock public document routes. Check identity, FDA or medicine boundaries, a live clinical-trial search, and status routes across 42 countries, including 3 compound-specific country findings.

Audit six controlled human studies, the failed 536-person pivotal obesity trial, oral and intravenous evidence, subcutaneous claim gaps, side effects, current prices, and worldwide verification routes.

Compare 7 exact-size BPC-157 research listings, including 5 confirmed in-stock rows, the $40.00 current low, and 4 in-stock public document routes. Check identity, FDA or medicine boundaries, a live clinical-trial search, and status routes across 42 countries, including 1 compound-specific country findings.

Separate BPC-157 animal research from small human records, the recruiting 120-participant Phase 2 hamstring trial, FDA safety findings, approval status, and worldwide verification routes.

Audit the accepted BPC-157 10 mg price change from $47.99 to $52.79, plus current matched-market range, availability, sources, and methodology.

BPC-157 and TB-500 frequently appear together in research-catalog searches, but they are distinct seller-labelled materials with separate identities, price boards, document trails, and FDA safety-context records. This page compares the current public US research-market footprint without treating either listing category as a medical option.

Obesity and metabolic pipeline. Long-acting amylin analogue · Once-weekly subcutaneous injection. 52 matched ClinicalTrials.gov records with status, phase, posted-results, country, US state, and site-level recruitment context.

Cagrilintide and CagriSema are related but not the same investigational treatment. Cagrilintide is a long-acting amylin analogue studied on its own. CagriSema is a fixed-dose combination of cagrilintide and semaglutide, a GLP-1 receptor agonist. REDEFINE 1 included separate randomized arms for cagrilintide alone and the combination. Novo Nordisk has submitted CagriSema to the FDA, while standalone cagrilintide continues in the RENEW Phase 3 program. Neither is currently FDA approved.

Cagrilintide and retatrutide are different investigational once-weekly peptides, and no randomized head-to-head trial has compared them. Cagrilintide is a long-acting amylin analogue now studied alone in the Phase 3 RENEW program. It is also the amylin component of CagriSema, but evidence for that combination cannot be assigned to cagrilintide alone. Retatrutide is a synthetic peptide designed to activate GIP, GLP-1, and glucagon receptors, with Phase 3 TRIUMPH results now reported. Separate trials cannot establish which program is more effective, safer, more convenient, or more sustainable for an individual. Neither drug is FDA approved, and FDA states that neither cagrilintide nor retatrutide can be used in compounding under federal law.

Cagrilintide and semaglutide are different peptide medicines and are not interchangeable. Cagrilintide is an investigational long-acting amylin analogue in the standalone RENEW Phase 3 program. Semaglutide is a GLP-1 receptor agonist with product-specific approvals, including WEGOVY for chronic weight management in defined populations. REDEFINE 1 randomized separate cagrilintide and semaglutide arms under one protocol and reported higher descriptive mean weight loss with semaglutide, but the cited sources do not establish a prespecified, statistically powered superiority test between those two monotherapy arms. Cagrilintide is not FDA approved and has no approved retail product or commercial price.

Obesity and metabolic pipeline. Amylin analogue + GLP-1 receptor agonist · Once-weekly subcutaneous injection. 30 matched ClinicalTrials.gov records with status, phase, posted-results, country, US state, and site-level recruitment context.

CagriSema and retatrutide are advanced but different investigational obesity drugs, and no head-to-head trial has compared them. CagriSema combines cagrilintide with semaglutide in a once-weekly injection and has been submitted to the FDA. Retatrutide is a once-weekly triple agonist targeting GIP, GLP-1, and glucagon receptors and has reported Phase 3 topline results. CagriSema is not approved merely because an application was filed, retatrutide is not approved, and separate trial percentages cannot determine which drug is better.

CagriSema and semaglutide were compared directly in the randomized Phase 3 REDEFINE 1 trial, which makes this comparison stronger than placing results from unrelated studies side by side. At 68 weeks, the trial-product estimand reported 22.7% mean weight loss with CagriSema and 16.1% with semaglutide. The same protocol used flexible dose escalation and compared CagriSema 2.4 mg/2.4 mg with semaglutide 2.4 mg in adults with obesity or overweight without type 2 diabetes. Those group results do not predict an individual winner. CagriSema remains investigational with an FDA application under review, while WEGOVY is an FDA-approved semaglutide product with product-specific labels and presentations.

CagriSema and survodutide are different investigational once-weekly obesity drugs with no head-to-head trial. CagriSema combines cagrilintide and semaglutide to engage amylin and GLP-1 pathways and is under FDA review. Survodutide is a single glucagon and GLP-1 receptor dual agonist with Phase 3 obesity and liver-focused evidence. Both have reported Phase 3 weight results, but only CagriSema has a publicly documented US application under review at this evidence check. Neither is approved for marketing, and their separate trials cannot establish which program is better.

Separate CJC-1295 with DAC from no DAC, then audit three healthy-adult biomarker papers, the terminated 192-participant Phase 2 trial, side effects, FDA votes, ipamorelin claims, prices, and global status.

Compare 3 exact-size CJC-1295 DAC research listings, including 2 confirmed in-stock rows, the $46.00 current low, and 2 in-stock public document routes. Check identity, FDA or medicine boundaries, a live clinical-trial search, and status routes across 42 countries, including 3 compound-specific country findings.

Compare 3 exact-size CJC-1295 no DAC research listings, including 2 confirmed in-stock rows, the $46.00 current low, and 1 in-stock public document routes. Check identity, FDA or medicine boundaries, a live clinical-trial search, and status routes across 42 countries, including 2 compound-specific country findings.

Audit the accepted CJC-1295 no DAC 5 mg price change from $67.99 to $74.79, plus current matched-market range, availability, sources, and methodology.

CJC-1295 no-DAC and CJC-1295 with DAC share a familiar catalog name while referring to different seller-labelled research formats. This comparison keeps their separate 5 mg price boards, availability states, evidence-access labels, and source pages visible so a shorthand search does not collapse two identities into one product row.

Track named obesity and metabolic programs with sponsor, mechanism, route, phase, country-specific approvals, trial identifiers, results, and unresolved claims.

Compare any two peptide, GLP-1 medicine, clinical pipeline, or qualified research-market records across aliases, FDA status, phase, sponsor, evidence, primary sources, and prices.

Scan all qualified research peptide boards by exact size, available price range, median, price per milligram, seller coverage, availability, public evidence, and Peptide Local editorial vial visual.

Compare 3 exact-size DSIP research listings, including 2 confirmed in-stock rows, the $27.49 current low, and 1 in-stock public document routes. Check identity, FDA or medicine boundaries, a live clinical-trial search, and status routes across 42 countries, including 0 compound-specific country findings.

Separate old intravenous sleep and withdrawal studies from modern subcutaneous DSIP claims, then check side effects, current prices, FDA status, and worldwide verification routes.

Audit the accepted DSIP 5 mg price change from $24.99 to $27.49, plus current matched-market range, availability, sources, and methodology.

Obesity and metabolic pipeline. cAMP-signalling-biased GLP-1 receptor agonist · Once-weekly subcutaneous injection. 15 matched ClinicalTrials.gov records with status, phase, posted-results, country, US state, and site-level recruitment context.

Ecnoglutide and mazdutide are different once-weekly peptide medicines with indication-specific approvals in China and no head-to-head trial against each other. Ecnoglutide is a cAMP-biased GLP-1 receptor agonist approved in China for type 2 diabetes and chronic weight management in 2026. Mazdutide activates GLP-1 and glucagon receptors and received Chinese approvals for chronic weight management and type 2 diabetes in 2025. Neither is FDA approved. Their pivotal weight percentages came from separate Chinese Phase 3 programs, so the results cannot establish that one approved product is more effective, safer, or more available than the other.

Ecnoglutide and retatrutide are separate peptide programs with no randomized head-to-head trial. Ecnoglutide is a once-weekly cAMP-biased GLP-1 receptor agonist with China approvals for chronic weight management and type 2 diabetes. Retatrutide is an investigational once-weekly GIP, GLP-1, and glucagon triple agonist with Phase 3 results but no marketing approval. Neither is FDA approved. Ecnoglutide's China approval does not make it globally available, and retatrutide's larger separate-trial headline cannot establish superiority over the approved Chinese ecnoglutide product.

Ecnoglutide and semaglutide are GLP-1 receptor agonists with different product and regulatory records. A direct randomized open-label Phase 2 study in 163 Chinese adults with obesity reported mean weight changes of 12.8% with ecnoglutide and 9.5% with semaglutide at week 20, with both groups using 2.4 mg maintenance doses. That is direct interim evidence for one protocol, not a universal winner claim. Ecnoglutide is approved in China for chronic weight management and type 2 diabetes but is not FDA approved. WEGOVY is an FDA-approved semaglutide product with its own label, forms, indications, and safety record.

FDA-approved GHRF-analog medicine. Lyophilized powder kit · Subcutaneous. BLA 022505 · FDA-approved prescription drug.

Obesity and metabolic pipeline. Selective amylin 1 receptor agonist · Once-weekly subcutaneous injection. 19 matched ClinicalTrials.gov records with status, phase, posted-results, country, US state, and site-level recruitment context.

Eloralintide and cagrilintide are different investigational once-weekly amylin-pathway drugs, and no human head-to-head trial has compared them. Eloralintide is designed to preferentially activate the amylin 1 receptor, while cagrilintide is a long-acting amylin analogue with a broader receptor profile. Eloralintide has a completed 48-week Phase 2 trial and a recruiting ENLIGHTEN Phase 3 program. Cagrilintide has Phase 3 monotherapy evidence from REDEFINE 1 and an active standalone RENEW program. Their percentages came from different trials, durations, dose strategies, estimands, and placebo groups. Neither drug is FDA approved, and the evidence does not establish which is more effective, safer, or more tolerable for an individual.

Eloralintide and retatrutide are separate investigational once-weekly peptide drugs from Lilly, and no head-to-head trial has compared them. Eloralintide is a single long-acting peptide that selectively activates the amylin 1 receptor. It does not activate GLP-1 or glucagon receptors, despite inaccurate descriptions on some commercial pages. Retatrutide is a synthetic peptide designed to activate GIP, GLP-1, and glucagon receptors. Eloralintide has a peer-reviewed 48-week Phase 2 result and recruiting Phase 3 trials. Retatrutide has Phase 3 TRIUMPH results from longer and different studies. The available evidence cannot establish which drug is better, and neither is FDA approved or a legitimate retail product.

Obesity and metabolic pipeline. Signal-biased GLP-1 + GIP receptor dual agonist · Once-weekly subcutaneous injection. 8 matched ClinicalTrials.gov records with status, phase, posted-results, country, US state, and site-level recruitment context.

Enicepatide and retatrutide are different investigational once-weekly obesity drugs, and no head-to-head trial has compared them. Enicepatide, formerly CT-388, activates GLP-1 and GIP receptors. Retatrutide activates those receptors plus the glucagon receptor. Enicepatide has sponsor-reported 48-week Phase 2 results and two recruiting Phase 3 ENITH trials. Retatrutide has Phase 3 TRIUMPH results from separate populations and longer study periods. Their headline percentages use different placebo adjustments, estimands, durations, doses, and trial designs, so they cannot establish a winner. Neither drug is FDA approved or a legitimate retail product.

Separate Epitalon identity, human-cell telomere findings, melatonin observations, missing insomnia and safety trials, current FDA compounding review, and worldwide verification routes.